Business Context and Reporting Period
This Form 8-K filing by TherapeuticsMD, Inc. (TXMD) was submitted on September 17, 2021, reporting an event that occurred on September 15, 2021. The company is incorporated in Nevada and its common stock trades on the Nasdaq Global Select Market.
Key Financial Metrics
This filing does not contain financial statements, revenue, profit, cash flow, margin, debt, or liquidity data. The report focuses exclusively on a regulatory compliance issue regarding the company's stock price.
Material Changes
The material change reported is the receipt of a deficiency letter from Nasdaq. The company's common stock closing bid price remained below the $1.00 minimum requirement for 30 consecutive business days ending September 15, 2021, violating Nasdaq Listing Rule 5450(a)(1).
Outlook, Risks, and Management Commentary
- Compliance Period: The company has 180 calendar days (until March 14, 2022) to regain compliance by maintaining a closing bid price of at least $1.00 for 10 consecutive business days.
- Remediation Options: Management is evaluating options to regain compliance, including effecting a reverse stock split.
- Delisting Risk: If compliance is not achieved within the initial period, the company may be eligible for an additional 180-day period if it meets other listing standards. Failure to cure the deficiency could result in delisting.
- Appeal Rights: The company retains the right to appeal any delisting determination to a Hearings Panel.
- Uncertainty: Management states there can be no assurance that the company will regain compliance or remain listed on Nasdaq.
Investor Verification Checklist
- Verify the current closing bid price of TXMD stock to assess progress toward the $1.00 threshold.
- Monitor future announcements regarding the potential execution of a reverse stock split.
- Check for any subsequent correspondence from Nasdaq regarding the status of the deficiency notice.
- Review the company's market value of publicly held shares to ensure eligibility for a potential second compliance period.